I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -1.81, missing the estimate of USD -1.2611.
EBIT: As of FY2026 Q2, the actual value is USD -35.04 M.
Net Loss
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of - $35.0 million for the three months ended June 30, 2026, compared to - $17.7 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $58.0 million, an increase from - $34.6 million for the six months ended June 30, 2025.
Total Operating Expenses
Total operating expenses increased by $17.0 million to $36.2 million for the three months ended June 30, 2026, from $19.2 million for the same period in 2025. This increase was primarily due to higher clinical development expenses, including a $10.0 million development milestone payment related to the CRB-701 licensing agreement.
Operating Loss
The company recorded an operating loss of - $36.2 million for the three months ended June 30, 2026, compared to an operating loss of - $19.2 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the operating loss was - $60.5 million, compared to - $38.9 million for the six months ended June 30, 2025.
Cash, Cash Equivalents, and Investments
As of June 30, 2026, Corbus Pharmaceuticals Holdings, Inc. held $117.9 million in cash, cash equivalents, and investments.
Cash Runway
Based on current operating plans and planned expenditures, Corbus Pharmaceuticals Holdings, Inc. expects its cash, cash equivalents, and investments to fund operations into 2028.
Key Operational Updates
Corbus Pharmaceuticals Holdings, Inc. obtained FDA clearance for the TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal cancer and concluded the last patient last visit in the CANYON-1 Phase 1b study of CRB-913 in obesity. The company also strengthened its senior leadership team with the appointment of a new Chief Medical Officer, Chief Business Officer, and Board Member.
Outlook and Guidance
Corbus Pharmaceuticals Holdings, Inc. expects to initiate enrollment in the TEMPO-1 study for CRB-701 in September 2026 and is on track to report topline data from the CANYON-1 Phase 1b study for CRB-913 in September 2026. The company anticipates reporting CRB-701 + Keytruda® combination data in Q1 2027 to support potential registration-enabling trials in first-line oropharyngeal cancer patients.